Company announcements · 19/11/20261 min read
Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Summary
30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-off Favorable safety and tolerability profile with very few patients needing dose reduction and no discontinuation for side effects on Q2W schedule Disease control...